Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pazopanib hydrochloride in patients with Von Hippel-Lindau syndrome has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Hippel-lindau Disease

Drugs mentioned

• Votrient (Pazopanib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Von Hippel-Lindau Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-05-02